Adenovirus-mediated delivery of a uPA/uPAR antagonist suppresses angiogenesis-dependent tumor growth and dissemination in mice

Gene Therapy

Volumn 5, Issue 8, 1998, Pages 1105-1113

  Li, H ^a   Lu, H ^b   Griscelli, F ^a   Opolon, P ^a   Sun, L Q ^b   Ragot, T ^a   Legrand, Y ^b   Belin, D ^c   Soria, J ^d   Soria, C ^b,e   Perricaudet, M ^a   Yeh, P ^a  

^a INSTITUT GUSTAVE ROUSSY   (France)

^b SAINT LOUIS HOSPITAL   (France)

^c UNIVERSITY OF GENEVA MEDICAL SCHOOL   (Switzerland)

^d HÔTEL DIEU   (France)

^e DIFEMA   (France)

Author keywords

Angiogenesis; Cancer; Cell invasion; Recombinant adenovirus; Urokinase

Indexed keywords

CELL SURFACE RECEPTOR; UROKINASE; UROKINASE RECEPTOR;

ADENOVIRUS; ANGIOGENESIS; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BREAST CARCINOMA; CELL INVASION; COLON CARCINOMA; GENE TARGETING; GENE THERAPY; HUMAN; HUMAN CELL; INJECTION SITE; LEWIS CARCINOMA; LIVER METASTASIS; LUNG METASTASIS; MOUSE; NEOVASCULARIZATION (PATHOLOGY); NONHUMAN; PRIORITY JOURNAL; TUMOR GROWTH; VIRUS RECOMBINANT; XENOGRAFT;

ADENOVIRIDAE; ANIMALIA; DNA VIRUSES; MURINAE;

EID: 7344262560     PISSN: 09697128     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.gt.3300742     Document Type: Article

References (53)

1. Folkman J. Angiogenesis in cancer, vascular, rheumatoid and other disease. Nature Med 1995; 1: 27-31.
2. Rak J, Filmus JRJ, Kerbel RS. Reciprocal paracrine interactions between tumor cells and endothelial cells: the 'angiogenesis progression hypothesis'. Eur J Cancer 1996; 32A: 2438-2450.
3. Roth JA, Christiano RJ. Gene therapy for cancer: what have we done and where are we going? J Natl Cancer Inst 1997; 88: 21-39.
4. O'Reilly MS et al. Angiostatin: a novel angiogenesis inhibitor that mediates the suppression of metastases by a Lewis lung carcinoma. Cell 1994; 79: 315-328.
5. Lu H et al. Blockage of urokinase receptor reduces in vitro the motility and deformability of endothelial cells. FEES Lett 1996; 380: 21-24.
6. Min HY et al. Urokinase receptor antagonists inhibit angiogenesis and primary rumor growth in syngeneic mice. Cancer Res 1996; 56: 2428-2433.
7. Maione TE et al. Inhibition of angiogenesis by recombinant human platelet factor-4 and related peptides. Science 1990; 247: 77-79.
8. Weinstat-Saslow DL et al. Transfection of thrombospondin I complementary DNA into a human breast carcinoma cell line reduces primary tumor growth, metastatic potential and angiogenesis. Cancer Res 1994; 54: 6504-6511.
9. Crowley CW et al. Prevention of metastasis by inhibition of the urokinase receptor. Proc Natl Acad Sci USA 1993; 90: 5021-5025.
10. Kobayashi H et al. Inhibition of metastasis of Lewis lung carcinoma by a synthetic peptide within the growth factor-like domain of urokinase in an experimental and spontaneous metastasis model. Int J Cancer 1994; 57: 727-733.
11. Lu H et al. Blockage of the urokinase receptor on the cell surface: construction and characterization of a hybrid protein consisting of the N-terminal fragment of human urokinase and human albumin. FEBS Lett 1994; 356: 56-59.
12. Ellis V, Behrendt N, Dano K. Plasminogen activation by receptor-bound urokinase, a kinetic study with cell-associated and isolated receptor. J Biol Chem 1991; 266: 12752-12758.
13. Mignatti PRM, Rifkin DB. Biology and biochemistry of proteinases in tumor invasion. Physiol Rev 1993; 73: 161-195.
14. He C et al. Tissue cooperation in a proteolytic cascade activating human interstitial collagenase. Proc Natl Acad Sci USA 1989; 86: 2632-2636.
15. Mazzieri R et al. Control of type IV collagenase activity by components of the urokinase-plasmin system: a regulatory mechanism with cell-bound reactants. EMBO J 1997; 16: 2319-2332.
16. Estreicher A et al. The receptor for urokinase type plasminogen activator polarizes expression of the protease to the leading edge of migrating monocytes and promotes degradation of enzyme inhibitor complexes. J Cell Biol 1990; 111- 783-792.
17. Wei Y et al. Identification of the urokinase receptor as an adhesion receptor for vitronectin. J Biol Chem 1994; 269: 32380-32388.
18. Simon DI et al. Macl (CD11b/CD18) and the urokinase receptor (CD87) form a functional unit on monocytic cells. Blood 1996; 88: 3185-3194.
19. Wei Y et al. Regulation of integrin function by the urokinase receptor. Science 1996; 273: 1551-1555.
20. Waltz DA et al. Plasmin and plasminogen activator inhibitor type 1 promote cellular motility by regulating the interaction between the urokinase receptor and vitronectin. J Clin Invest 1997; 100: 58-67.
21. Rifkin D et al Growth factor control of extracellular proteolysis. Cell Diff Dev 1990; 32: 313-318.
22. Bacharach E, Itin A, Keshet E. In vivo patterns of expression of urokinase and its inhibitor PAI-1 suggest a concerted role in regulating physiological angiogenesis. Proc Natl Acad Sci USA 1992; 89: 10686-10690.
23. Naldini L et al. Extracellular proteolytic cleavage by urokinase is required for activation of hepatocyte growth factor/scatter factor. EMBO J 1992; 11: 4825-4833.
24. Koolwijk P et al. Cooperative effect of TNFalpha, bFGF and VEGF on the formation of tubular structure of human microvasculature endothelial cells in a fibrin matrix: role of urokinase activity. J Cell Biol 1996; 132: 1177-1188.
25. Plouet J et al. Extracellular cleavage of the vascular endothelial growth factor 189 amino acid form by urokinase is required for its mitogenic effect. J Biol Chem 1997; 272: 13390-13396.
26. Sappino AP, Busso N, Belin D, Vassalli JD. Increase of urokinase-type plasminogen activator gene expression in human lung and breast carcinomas. Cancer Res 1987; 47: 4043-4046.
27. Schmitt M, Janicke F, Graeff H. Tumor-associated proteases. Fibrinolysis 1992; 6: 3-26.
28. Kobayashi H et al. Increased cell-surface urokinase in advanced ovarian cancer. Jpn J Cancer Res 1993; 84: 633-640.
29. Yamamoto M et al. Expression and localization of urokinasetype plasminogen activator in human astrocytomas in vivo. Cancer Res 1994; 54: 3656-3661.
30. Foekens JA et al. Urokinase-type plasminogen activator and its inhibitor PAI-1: predictors of poor response to tamoxifen therapy in recurrent breast cancer. J Natl Cancer Inst 1995; 87: 751-756.
31. Park IK et al. Co-expression of urokinase-type plasminogen activator and its receptor in human gastric cancer cell lines correlates with their invasiveness and tumorigenicity. Int J Cancer 1997; 71: 867-873.
32. Pyke C et al. Urokinase-type plasminogen activator is expressed in stromal cells and its receptor in cancer cells at invasive foci in human colon adenocarcinomas. Am J Pathol 1991; 138: 1059-1067.
33. Shapiro RL et al. Induction of primary cutaneous melanocytic neoplasms in urokinase-type plasminogen activator (uPA) deficient and wild-type mice: cellular blue nevi invade but do not progress to malignant melanoma in uPA-deficient animals. Cancer Res 1996; 56: 3597-3604.
34. Belin D et al. Cloning, nucleotide sequencing and expression of cDNAs encoding mouse urokinase-type plasminogen activator. Eur J Biochem 1985; 148: 225-232.
35. Appella E et al. The receptor binding sequence of urokinase: a biological function for the growth factor module of proteases. J Biol Chem 1987; 262: 4437-4440.
36. Magdolen V et al. Systemic mutational analysis of the receptorbinding region of the human urokinase-type plasminogen activator. Eur J Biochem 1996; 237: 743-751.
37. Weidner N, Semple JP, Welch WR. Tumor angiogenesis and metastasis correlation in invasive breast carcinoma. New Engl J Med 1991; 324: 1-8.
38. 5 promote internalization but not virus attachment. Cell 1993; 73: 309-319.
39. 3 antagonists promote tumor regression by inducing apoptosis of angiogenic blood vessels. Cell 1994; 79: 1157-1164.
40. Vogel CA, Galmiche MC, Buchegger F. Radioimmunotherapy and fractionated radiotherapy of human colon cancer liver metastases in nude mice. Cancer Res 1997; 57: 447-453.
41. Burrows FJ, Thorpe PE. Eradication of large solid tumors in mice with an immunotoxin directed against tumor vasculature. Proc Natl Acad Sci USA 1993; 90: 8996-9000.
42. Kim KJ et al. Inhibition of vascular endothelial growth factorinduced angiogenesis suppresses tumor growth in vivo. Nature 1993; 362: 841-844.
43. Huang X et al. Tumor infarction in mice by antibody-directed targeting of tissue factor to tumor vasculature. Science 1997; 275: 547-550.
44. Dvorak HF, Nagy JA, Dvorak JT, Dvorak AM. Identification and characterization of the blood vessels of solid tumors that are leaky to circulating macromolecules. Am J Pathol 1988; 133: 95-109.
45. Liotta L, Kleinerman J, Saidel G. Quantitative relationships of intravascular tumor cells, tumor vessels and pulmonary metastases following tumor implantation. Cancer Res 1974; 34: 997-1004.
46. Holmgren L, O'Reilly MS, Folkman J. Dormancy of micrometastasis: balanced proliferation and apoptosis in the presence of angiogenesis suppression. Nature Med 1995; 1: 149-153.
47. Tanaka T et al. Viral vector-mediated transduction of a modified platelet factor 4 cDNA inhibits angiogenesis and tumor growth. Nature Med 1997; 3: 437-442.
48. Griscelli F et al. Angiostatin gene transfer: inhibition of tumor growth in vivo by blockage of endothelial cell proliferation asso- ciated with a mitosis arrest. Proc Natl Acad Sci USA 1998; 95: 6367-6372.
49. Dedieu J-F et al. Long-term gene delivery into the liver of immunocompetent mice with El/E4-defective adenoviruses. J Virol 1997; 71: 4626-4637.
50. Feng M et al. Stable in vivo gene transduction via a novel adenoviral/retroviral chimeric vector. Nature Biotechnol 1997; 15: 866-870.
51. Pepper MS et al. Upregulation of urokinase receptor expression on migrating endothelial cells. J Cell Biol 1993; 122: 673-684.
52. Stratford-Perricaudet LD, Makeh I, Perricaudet M, Briand P. Widespread long-term gene transfer to mouse skeletal muscles and heart via an adenovirus vector. J Clin Invest 1992; 90: 626-630.
53. Yeh P, Perricaudet M. Advances in adenoviral vectors: from genetic engineering to their biology. FASEB J 1997; 11: 615-623.